PTGXのニュース
Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference 2022/12/21 21:05:00 PR Newswire
NEWARK, Calif., Dec. 21, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will offer a corporate presentation and host one-on-one meetings with investors…
These strategies will help Protagonist Therapeutics Inc. (PTGX) succeed 2022/12/09 13:40:00 US Post News
Protagonist Therapeutics Inc. (NASDAQ:PTGX) marked $7.78 per share on Thursday, up from a previous closing price of $7.65. While Protagonist Therapeutics Inc. has overperformed by 1.70%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PTGX fell by -77.14%, with highs and lows ranging from $37.04 to […]
Short Volatility Alert: PROTAGONIST THERAP 2022/11/16 19:27:04 Benzinga
On Tuesday, shares of PROTAGONIST THERAP (NASDAQ: PTGX ) experienced volatile short activity. After the activity, the stock price went down -3.25% to $8.04. The overall sentiment for PTGX has been Bearish. The signal from the volatility alert is trending Bullish. Therefore, the recommendation is to Strong Buy. The volatility alert was produced on the prior trading date, 11/15/2022 with a volatility change of +36.45%. The current volatility indicator stands at 8.196. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the … Full story available on Benzinga.com
Results from Protagonist Therapeutics Inc. (PTGX) show risk 2022/11/10 15:00:00 US Post News
Protagonist Therapeutics Inc. (NASDAQ:PTGX) marked $7.71 per share on Wednesday, down from a previous closing price of $7.74. While Protagonist Therapeutics Inc. has underperformed by -0.39%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PTGX fell by -78.29%, with highs and lows ranging from $38.11 to […]
Protagonist GAAP EPS of -$0.64 beats by $0.23 2022/11/08 22:44:29 Seeking Alpha
Protagonist press release (PTGX): Q3 GAAP EPS of -$0.64 beats by $0.23.The company expects current cash, cash equivalents and marketable securities of $267.4M to be sufficient to…
Protagonist Therapeutics (PTGX) Investor Presentation - Slideshow (NASDAQ:PTGX) 2022/08/05 20:04:41 Seeking Alpha
The following slide deck was published by Protagonist Therapeutics, Inc.
Protagonist GAAP EPS of -$0.84 beats by $0.10 2022/08/04 21:34:25 Seeking Alpha
Protagonist press release (PTGX): Q2 GAAP EPS of -$0.84 beats by $0.10.Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of June…
Have you been able to find a good deal on Protagonist Therapeutics Inc.’s shares? 2022/08/04 15:48:00 US Post News
The share price of Protagonist Therapeutics Inc. (NASDAQ:PTGX) rose to $11.21 per share on Wednesday from $10.63. While Protagonist Therapeutics Inc. has overperformed by 5.46%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PTGX fell by -77.24%, with highs and lows ranging from $50.54 to $6.91, […]
Why Protagonist Therapeutics Inc. (NASDAQ: PTGX) Stock Should Not Be Discarded By Investors In 2022 2022/07/12 13:30:00 Marketing Sentinel
In the last trading session, 1.52 million shares of the Protagonist Therapeutics Inc. (NASDAQ:PTGX) were traded, and its beta was 2.51. Most recently the company’s share price was $9.00, and it changed around -$0.62 or -6.44% from the last close, which brings the market valuation of the company to $389.70M. PTGX currently trades at a … Why Protagonist Therapeutics Inc. (NASDAQ: PTGX) Stock Should Not Be Discarded By Investors In 2022 Read More »
Protagonist Therapeutics (PTGX) Presents At Jefferies Healthcare Conference - Slideshow (NASDAQ:PTGX) 2022/06/15 15:55:27 Seeking Alpha
The following slide deck was published by Protagonist Therapeutics, Inc.
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update 2022/02/28 21:05:00 PR Newswire
NEWARK, Calif., Feb. 28, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. "This past quarter and the year leading up…
Protagonist Therapeutics Inc. (NASDAQ:PTGX) Is Likely To Perform Well Over The Long Term. Lost Nearly -13.83% Last Month. 2022/02/26 15:00:00 Marketing Sentinel
In last trading session, Protagonist Therapeutics Inc. (NASDAQ:PTGX) saw 0.54 million shares changing hands with its beta currently measuring 2.28. Company’s recent per share price level of $24.49 trading at $0.24 or 0.99% at ring of the bell on the day assigns it a market valuation of $1.20B. That closing price of PTGX’s stock is … Protagonist Therapeutics Inc. (NASDAQ:PTGX) Is Likely To Perform Well Over The Long Term. Lost Nearly -13.83% Last Month. Read More »
Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference 2022/02/10 12:00:00 Kwhen Finance
Protagonist Therapeutics, Inc. (PTGX) Fell Out Of Favor With Hedge Funds 2022/01/12 16:26:26 Insider Monkey
In this article we will check out the progression of hedge fund sentiment towards Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and determine whether it is a good investment right now.
Protagonist Therapeutics (NASDAQ:PTGX) versus Syndax Pharmaceuticals (NASDAQ:SNDX) Financial Survey 2021/12/22 08:14:42 Dakota Financial News
Protagonist Therapeutics (NASDAQ:PTGX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Profitability This table compares Protagonist Therapeutics and Syndax Pharmaceuticals net margins, return on equity and []